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1Computed tomographic angiography (CTA) and magnetic resonance angiography (MRA) are increasingly used 
to assess arterial patency in patients with ischemic stroke.1,2 
Angiography may also improve selection of patients with 
ischemic stroke for treatment with intravenous thrombolyt-
ics. However, it is unclear if arterial obstruction, or collateral 
Background and Purpose—Computed tomographic angiography and magnetic resonance angiography are used increasingly 
to assess arterial patency in patients with ischemic stroke. We determined which baseline angiography features predict 
response to intravenous thrombolytics in ischemic stroke using randomized controlled trial data.
Methods—We analyzed angiograms from the IST-3 (Third International Stroke Trial), an international, multicenter, 
prospective, randomized controlled trial of intravenous alteplase. Readers, masked to clinical, treatment, and outcome 
data, assessed prerandomization computed tomographic angiography and magnetic resonance angiography for presence, 
extent, location, and completeness of obstruction and collaterals. We compared angiography findings to 6-month 
functional outcome (Oxford Handicap Scale) and tested for interactions with alteplase, using ordinal regression in 
adjusted analyses. We also meta-analyzed all available angiography data from other randomized controlled trials of 
intravenous thrombolytics.
Results—In IST-3, 300 patients had prerandomization angiography (computed tomographic angiography=271 and magnetic 
resonance angiography=29). On multivariable analysis, more extensive angiographic obstruction and poor collaterals 
independently predicted poor outcome (P<0.01). We identified no significant interaction between angiography findings 
and alteplase effect on Oxford Handicap Scale (P≥0.075) in IST-3. In meta-analysis (5 trials of alteplase or desmoteplase, 
including IST-3, n=591), there was a significantly increased benefit of thrombolytics on outcome (odds ratio>1 indicates 
benefit) in patients with (odds ratio, 2.07; 95% confidence interval, 1.18–3.64; P=0.011) versus without (odds ratio, 0.88; 
95% confidence interval, 0.58–1.35; P=0.566) arterial obstruction (P for interaction 0.017).
Conclusions—Intravenous thrombolytics provide benefit to stroke patients with computed tomographic angiography or 
magnetic resonance angiography evidence of arterial obstruction, but the sample was underpowered to demonstrate 
significant treatment benefit or harm among patients with apparently patent arteries.
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supply, influences the response to intravenous thrombolyt-
ics. A retrospective stroke registry observed a trend for more 
favorable clinical outcome after intravenous alteplase in 
patients with intracranial arterial occlusion versus those with 
no/minimal obstruction in whom it was unclear if intravenous 
alteplase was beneficial or not.3
Few randomized controlled trials (RCTs) of intrave-
nous thrombolytics included CTA or MRA to determine 
whether angiographic obstruction–occlusion or collateral 
supply modifies the treatment response. A pooled analysis 
of DIAS (Desmoteplase in Acute Ischemic Stroke), DIAS-
2, and DEDAS (Dose Escalation of Desmoteplase for Acute 
Ischemic Stroke) demonstrated that patients with complete 
arterial occlusion or severe obstruction had better outcomes 
after desmoteplase than placebo, but in patients with minimal 
obstruction or normal arteries, there was no significant dif-
ference between desmoteplase versus placebo.4 In EPITHET 
(Echoplanar Imaging Thrombolytic Evaluation Trial), patients 
with middle cerebral artery (MCA) rather than internal carotid 
artery (ICA) obstruction demonstrated better outcome after 
intravenous alteplase, but they did not test for an alteplase–
arterial patency interaction.5
The IST-3 (Third International Stroke Trial) was a large 
(n=3035) RCT that tested whether intravenous alteplase given 
within 6 hours of ischemic stroke improved functional out-
come at 6 months compared with control.6 In IST-3, some 
centers routinely performed CTA or MRA prerandomization. 
As prespecified,7 we investigated whether arterial obstruction 
or collateral status on prerandomization CTA and MRA influ-
enced outcome after alteplase versus control. In addition, we 
meta-analyzed all RCTs of intravenous thrombolytics in isch-
emic stroke with baseline angiography data.
Methods
Third International Stroke Trial
IST-3 was an international, multicenter, PROBE trial (prospective, 
randomized, open-label, blinded end point) of intravenous alteplase 
in acute ischemic stroke. Ethical approval was granted by the 
Multicentre Research Ethics Committees, Scotland (MREC/99/0/78) 
and by local ethics committees. Enrollment, randomization, data 
collection and analysis, and adherence to CONSORT (Consolidated 
Standards of Reporting Trials) recommendations have been pub-
lished.6,8,9 Briefly, adults with acute stroke of any severity, in whom 
CT or MR imaging had excluded intracranial hemorrhage and struc-
tural stroke mimics, who did not meet the prevailing license crite-
ria for alteplase but had no clear contraindication to treatment, were 
eligible for the trial if treatment could be started within 6 hours of 
known stroke onset. Informed consent was obtained for all patients. 
Baseline stroke severity before randomization was assessed with the 
National Institutes of Health Stroke Scale (NIHSS). After entry of 
baseline data, patients were randomly allocated to immediate intra-
venous alteplase (0.9 mg/Kg) or control. Functional outcome was 
assessed at 6 months with the Oxford Handicap Scale (OHS), which 
is similar to the modified Rankin Scale.
Angiographic Imaging in IST-3
IST-3 centers that routinely performed CTA or MRA in stroke sub-
mitted these images for assessment. Here, we include only IST-3 
patients with angiography performed prerandomization. Images 
were anonymized and uploaded to a web-based rating platform, the 
Systematic Image Review System V2. Systematic Image Review 
System V2 provides secure anonymized image viewing via a browser 
(www.neuroimage.co.uk) and simultaneously records the scan inter-
pretation using a validated proforma10,11 (http://www.sbirc.ed.ac.uk/
research/imageanalysis.html).
All angiographic imaging in IST-3 was assessed centrally by 
a panel of 10 experts in stroke imaging (7 neuroradiologists and 3 
neurologists/stroke physicians). Readers were masked to all clinical, 
treatment, and functional outcome data and to imaging from different 
time points (concurrent plain scans were viewed with angiography). 
IST-3 angiography was analyzed independently from the plain CT 
and MR imaging scans of the main IST-3 trial.
Scan readers recorded the presence, location, and severity of all 
arterial obstructions, largest affected artery first plus ≤2 additional 
segments (Table I in the online-only Data Supplement). Locations 
were ICA, MCA, anterior cerebral artery, posterior cerebral artery, 
vertebral artery, or basilar artery. We grouped arterial segments as 
proximal (ICA, main stem MCA, vertebral artery, and basilar artery) 
or distal (Sylvian branch of MCA, anterior cerebral artery, and pos-
terior cerebral artery).
Readers coded the focus of arterial obstruction using a modified 
Thrombolysis in Cerebral Infarction (TICI) and the IST-3 angiogra-
phy scores.7,12 Both are scalar and range from occlusion (0), through 
decreasing grades of obstruction, to normal (3 for TICI and 4 for IST-
3). For this analysis, we categorized the IST-3 score 0 to 2b and the 
TICI score 0 to 2a as obstruction and IST-3 score 3 to 4 and the TICI 
score 2b to 3 as patent.
Readers also coded the clot burden score in patients with anterior 
circulation obstruction (subtracts the sum of the number of arterial 
segments affected from 10,13 where score 0=all segments affected and 
10=no segments affected) and the collateral vessel supply in patients 
with ICA or MCA obstruction (categorized as good where the entire 
MCA distal to obstruction reconstituted with contrast, moderate 
where there was some MCA branch reconstitution, or poor if only 
distal superficial branches reconstituted).14
We tested previously interobserver reliability for the IST-3 panel’s 
CTA assessments (but because of the small number of cases, not 
MRA) on 15 representative scans,15 finding substantial agreement 
for arterial obstruction on TICI, IST-3 angiography, and clot burden 
scores (Krippendorff α=0.60, 0.66, and 0.63, respectively) and mod-
erate agreement for collateral score (0.56).
Statistical Analysis: IST-3 Angiography Data
For univariate analysis of normally distributed data, we compared 
ratios and means with t tests; for nonparametric data, we used Mann–
Whitney U tests to compare medians and Spearman ρ to assess for 
correlation. We used multifactor ANOVA to look for interactions 
between combinations of angiographic findings and OHS. To test for 
associations between angiography findings, alteplase versus control 
and outcome, we used multivariable ordinal regression to calculate 
common odds ratios (ORs) with OHS at 6 months as the dependent 
variable. We first tested the impact of different angiography charac-
teristics on outcome individually, controlled for patient age, NIHSS, 
time from stroke onset to scan, and alteplase treatment allocation 
(here, OR <1 indicates worse outcome with alteplase). We then com-
pared alteplase treatment effect on outcome (here, OR <1 favors 
control) for dichotomies (more normal versus less normal) of each 
angiography characteristic individually, controlled for patient age, 
NIHSS, and time from stroke onset to scan and tested for treatment 
interactions by comparing ORs between dichotomies. For this lat-
ter analysis only, we dichotomized clot burden and collateral scores 
as better (8–9 and good) versus worse (0–7 and moderate–poor, 
respectively).
Meta-Analysis
We identified all RCTs comparing intravenous thrombolytics with 
control among patients with baseline angiography after ischemic 
stroke from the Cochrane Collaboration systematic review on 
“Thrombolysis for Acute Ischaemic Stroke”16 and contacted investi-
gators for additional data where necessary. We used the random effects 
method to perform 2 separate meta-analyses to obtain summary ORs 
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for the effect of intravenous thrombolytics (any formulation or dose) 
on outcome (OHS or mRS at 3–6 months) in patients with (1) arte-
rial obstruction (IST-3 angiography score 0 to 2b or Thrombolysis 
in Myocardial Infarction 0–1 or 0–2) versus patent vessels (IST-3 
angiography score 3–4 or Thrombolysis in Myocardial Infarction 
2–3 or 3) and (2) ICA versus MCA obstruction, including tests for 
interactions between intravenous thrombolytics and arterial status on 
functional outcome. We tested for between-study heterogeneity using 
I2 statistics. We followed Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) guidelines for meta-analysis 
reporting (Appendix II in the online-only Data Supplement).
We used Comprehensive Meta-Analysis software (Biostat, 
Englewood, NJ) to compute summary ORs and test for interactions. 
We performed all other analyses using IBM SPSS Statistics soft-
ware, version 20.0 (IBM Corporation, Armonk, NY). We considered 
P<0.05 significant.
Results
Third International Stroke Trial
From 3035 IST-3 patients, 300 (9.9%) had prerandomization 
angiography, 271 with CTA, 29 with MRA. Compared with 
the full IST-3 trial, patients with angiography had less severe 
strokes at baseline (median NIHSS score of 9 versus 11; 
P=0.003), had baseline scanning slightly later (mean 180 ver-
sus 164 minutes; P<0.0001) and were randomized slightly later 
after stroke (mean 241 versus 231 minutes; P=0.019), and had 
better 6-month outcomes (median OHS 3 versus 4; P=0.001). 
There was no significant difference in age, sex, or treatment 
allocation between patients with angiograms versus the full 
IST-3 trial (Table II in the online-only Data Supplement). 
Among patients with angiography, there were no significant 
differences between alteplase and control groups (Table 1).
Angiography Findings: IST-3
In IST-3, 146 of 300 (48.7%) patients had intracranial arterial 
obstruction on angiography (Table 2). ICA (47/146=32.2%) 
or MCA mainstem (57/146=39.0%) obstruction was most 
common. For those with arterial obstruction, >1 arterial 
segment was affected in approximately half, 2 segments in 
54 of 146 (37.0%), and 3 segments in 15 of 146 (10.3%). 
From 288 patients with an IST-3 Angiography score, 104 
(36.1%) scored 0 to 2b, whereas 184 (63.9%) scored 3 to 4 
(Table 2 for concurrent TICI scores). The median clot burden 
score was 8 (2 segments affected). Similar proportions had 
good (48/135=35.6%), moderate (37/135=27.4%), or poor 
(50/135=37.0%) collateral scores.
Angiography, Stroke Severity, and 
Functional Outcome: IST-3
On univariate analysis, all categories of angiographic abnor-
mality were associated with significantly worse baseline 
stroke severity and poorer 6-month outcome (P<0.0001 for 
most; Table III in the online-only Data Supplement). A 3-way 
ANOVA found no interaction between any combination 
of the effects of TICI, clot burden, and collateral scores on 
OHS (F=0.814; P=0.564; Table IV in the online-only Data 
Supplement). In multivariable ordinal regression analysis, 
controlled for age, NIHSS, time from stroke onset to scan 
and alteplase treatment allocation; having a greater number 
of obstructed arterial segments (OR, 0.41; 95% confidence 
interval [CI], 0.22–0.76; P=0.005), a worse clot burden score 
(OR, 0.78; 95% CI, 0.62–0.97; P=0.026), or poorer collaterals 
(OR, 0.53; 95% CI, 0.32–0.85; P=0.009) were all indepen-
dent predictors of worse 6-month outcome, but not proximal 
versus distal (or ICA versus MCA) arterial obstruction, or the 
residual arterial caliber at the point of obstruction on IST-3 
angiography or TICI scores (Table 3).
Angiography and Effect of 
Intravenous Alteplase: IST-3
In IST-3, in multivariable ordinal regression, we found no sig-
nificant interactions between any individual angiogram fea-
ture and the effect of alteplase on 6-month OHS (Figure 1). 
There was a nonsignificant trend toward better outcomes after 
alteplase versus control among patients with obstructed (OR, 
1.86; 95% CI, 0.76–4.53; P=0.171) versus patent (OR, 0.72; 
95% CI, 0.42–1.25; P=0.241) arteries on the IST-3 angiogra-
phy score, P=0.075 for interaction (Figures 1 and 2).
Angiography and Effect of Intravenous 
Thrombolytics: Meta-Analysis of All Trials
We identified 11 RCTs of intravenous thrombolytics for 
ischemic stroke with baseline angiography (Figure I in the 
online-only Data Supplement) from which data were avail-
able for meta-analysis of 4 trials in addition to IST-3 (n=591). 
We included 2 trials of intravenous alteplase (288 patients 
from IST-3 and 87 from EPITHET19) and 3 trials of intrave-
nous desmoteplase (216 patients from DIAS, DIAS-2, and 
DEDAS).20–22 Meta-analysis showed that patients with arterial 
obstruction were significantly more likely to have better func-
tional outcome with intravenous thrombolytics versus control 
Table 1. Comparison of Baseline Data and Main Outcomes 
in IST-3 (Third International Stroke Trial) Patients With 
Angiography Allocated to Alteplase and Control (n=300)
 
Alteplase, 
n=147
Control, 
n=153
P Value for 
Difference
Age, y, median (IQR) 81 (73–86) 80 (69–85) 0.274
Male sex (%) 63 (42.9) 69 (45.1) 0.697
Time from stroke onset to 
baseline scan, min, mean (SD)
184 (82) 175 (78) 0.344
Time from stroke onset to 
randomization, min, mean (SD)
243 (82) 238 (79) 0.584
Baseline NIHSS, median (IQR) 10 (5–17) 9 (5–16) 0.603
Clinical stroke syndrome17 (%) 0.590
  TACI 49 (33.3) 50 (32.7)  
  PACI 64 (43.5) 68 (44.4)  
  LACI 11 (7.5) 14 (9.2)  
  POCI 23 (15.6) 20 (13.1)  
ASPECTS,18 median (IQR) 10 (8–10) 10 (8–10) 0.914
6-mo OHS, median (IQR) 3 (1–5) 3 (1–5) 0.726
6-mo mortality (%) 32 (21.8) 35 (22.9) 0.819
ASPECTS indicates Alberta Stroke Program Early CT Score; IQR, interquartile 
range; LACI, lacunar infarct; NIHSS, National Institutes of Health Stroke Scale; 
OHS, Oxford Handicap Scale; PACI, partial anterior circulation infarct; POCI, 
posterior circulation infarct; and TACI, total anterior circulation infarct.
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(OR, 2.07; 95% CI, 1.18–3.64; P=0.011) than were patients 
with patent arteries (intravenous thrombolytics versus con-
trol, OR, 0.88; 95% CI, 0.58–1.35; P=0.566), for interaction 
P=0.017 (Figure 3).
For meta-analysis of ICA versus MCA obstruction, data were 
only available from IST-3 and EPITHET (n=135+54=189, 
respectively) and we did not find any difference between 
response to intravenous thrombolytics in patients with ICA 
versus MCA obstruction (ICA obstruction: OR, 0.65; 95% CI, 
0.06–6.89; P=0.720; MCA obstruction: OR, 1.92; 95% CI, 
0.90–4.09; P=0.090) for interaction P=0.391 (Figure II in the 
online-only Data Supplement).
Discussion
This analysis of CTA and MRA data from 5 RCTs of intra-
venous thrombolytics (alteplase and desmoteplase), includ-
ing IST-3, comprising 591 patients treated within 6 hours of 
stroke, indicates that patients with angiographic obstruction/
occlusion benefit significantly more from intravenous throm-
bolytics than patients without arterial obstruction. Therefore, 
where endovascular therapy is not available,23 intravenous 
thrombolytics remain an important treatment. The significant 
interaction between angiography appearance and intravenous 
thrombolytics does not mean that patients with normal baseline 
angiography gain no benefit from intravenous thrombolytics24; 
the meta-analysis was neutral in this group, showing neither 
benefit or harm, but the sample is too small to exclude modest 
benefit or harm. It is important to remember that patients with 
normal angiograms may have arterial obstruction(s) too small 
to see on CTA/MRA, and intravenous thrombolytics may be 
beneficial in these patients.
In IST-3, we also demonstrate that having a greater num-
ber of obstructed arterial segments or poor collateral supply 
was associated with poor 6-month functional outcome, inde-
pendent of stroke severity and alteplase treatment, that is, 
alteplase was less likely to improve outcome in these patients. 
Those with a greater number of obstructed segments may, 
therefore, have the most to gain from endovascular therapy, 
which several RCTs have recently shown to be superior to 
  1 1 1
  0 0 1
Collateral score, n=135
  Good 22 26
  Moderate 23 14
  Poor 22 28
Clot burden and collateral scores were calculated only with anterior circulation 
obstruction. Obstruction was obscured or too peripheral for calculation of an 
IST-3 angiography, TICI or clot burden score in 12 cases. Not all patients with 
normal IST-3 angiography scores had normal TICI scores and vice versa. ACA 
indicates anterior cerebral artery; CTA, computed tomographic angiography; 
ICA, internal carotid artery; IST-3, Third International Stroke Trial; MCA, middle 
cerebral artery; MRA, magnetic resonance angiography; PCA, posterior cerebral 
artery; and TICI, Thrombolysis in Cerebral Infarction.
*Readers were asked is there an abnormal/occluded artery on CTA/MRA?
Table 2. Angiography Findings for the 300 Patients 
Randomized in IST-3 With CTA or MRA
 Alteplase, n=147 Control, n=153
Angiographic obstruction, n=300*
  Yes 72 74
  No 75 79
No. of obstructed arterial segments, n=146
  1 35 42
  2 29 25
  3 8 7
Largest arterial segment obstructed, n=146
  ICA 27 20
  MCA mainstem 25 32
  MCA Sylvian branch 15 16
  Basilar 2 3
  Vertebral 2 1
  Other 1 2
  ACA 0 0
  PCA 0 0
Location of angiographic obstruction, n=142
  Distal vessel only 13 13
  Proximal vessel only 21 25
  Proximal and distal 36 34
IST-3 angiography score, n=288
  4 75 80
  3 12 17
  2b 7 9
  2a 8 4
  1 15 17
  0 23 21
TICI score, n=288
  3 80 83
  2b 12 20
  2a 11 6
  1 11 18
  0 26 21
Clot burden score, n=123
  9 21 17
  8 12 17
  7 6 8
  6 4 6
  5 6 3
  4 4 4
  3 4 3
  2 3 2
(Continued )
Table 2. Continued
 Alteplase, n=147 Control, n=153
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intravenous alteplase alone among patients with angiogra-
phy-confirmed proximal intracranial arterial obstruction.25 
Consistent with our results, post hoc analysis of one of these 
endovascular treatment trials demonstrated that patients with 
poor collateral supply had poorer outcomes than those with 
good collaterals.26
We could not confirm in the meta-analysis that patients 
with MCA versus ICA obstruction responded differently to 
thrombolytics, but the sample available for this comparison 
was very small. In general, we were unable to identify avail-
able comparable trial data for most of the other angiogra-
phy characteristics assessed in IST-3. To better understand 
thrombolysis–angiography interactions, future RCTs of acute 
stroke therapy with CTA or MRA should examine location, 
extent, completeness of arterial obstruction, and adequacy of 
collaterals, to refine how these findings could help treatment 
decisions.
Strengths and Limitations
Strengths of IST-3 include our use of robust, validated meth-
ods for scan management, of scoring angiograms,7 with 
blinding of readers and moderate to substantial interobserver 
agreement.15 Limitations of IST-3, discussed previously, 
include the potential introduction of bias through its open 
design.6 Angiographic imaging was not a requirement of IST-
3, but some centers performed baseline CTA or MRA for 
ischemic stroke routinely; therefore, the angiography analy-
sis was preplanned to maximize knowledge gained from an 
RCT. The results of angiography were not used to determine 
trial eligibility, and at the time of IST-3 enrollment, there were 
virtually no data on how angiography results should be used 
in this context. Therefore, clinical uncertainty as to whether 
treatment with alteplase would be beneficial existed even 
for patients with large artery obstruction. Angiography was 
however performed in only 10% of IST-3 centers, potentially 
reflecting selection bias and restricting generalizability of the 
findings to all current stroke centers. Nevertheless, IST-3 angi-
ography represents real-world practice, where nearly 50% had 
angiographic obstruction27 and with 300 patients, is the largest 
angiography data set from an RCT of intravenous alteplase in 
ischemic stroke. Despite this, the wide CIs indicate that our 
sample is underpowered to estimate the effect of angiogra-
phy findings on alteplase response. We used dichotomies of 
better versus worse angiography scoring to simplify scalar 
data in IST-3. We acknowledge that different dichotomies of 
the same scalar data could provide different results, but we 
felt that our technique nevertheless provided a meaningful 
and useable summary. For the meta-analysis, slight inconsis-
tencies in angiogram scoring between trials mean that there 
is some overlap between categories (eg, Thrombolysis in 
Myocardial Infarction=2 is included in the better category for 
EPITHET but the worse category for the desmoteplase trials). 
Efforts to standardize angiogram rating in future trials should 
Table 3. Multivariable Ordinal Regression Analyses Testing 
for Independent Associations Between Angiographic Findings 
in IST-3 and 6-Month Functional Outcome on the OHS
 Odds Ratio
95% Confidence 
Interval P Value
Increased number of obstructed 
arterial segments, n=146
0.41 0.22–0.76 0.005
Obstructed proximal vs distal 
artery, n=142
0.45 0.20–1.02 0.055
Obstructed ICA vs MCA, n=135 0.85 0.40–1.81 0.679
Worse IST-3 angiography score, 
n=288
0.90 0.78–1.04 0.145
Worse TICI score, n=288 0.85 0.71–1.01 0.062
Worse Clot Burden Score, n=123 0.78 0.62–0.97 0.026
Poor Collateral Score, n=135 0.53 0.32–0.85 0.009
Odds ratio <1 indicates a worse outcome. Six-month OHS was the dependent 
variable for each separate model. Results are adjusted for patient age, time 
from stroke onset to scan, stroke severity (National Institutes of Health Stroke 
Scale), and alteplase treatment allocation. ICA indicates internal carotid artery; 
IST-3, Third International Stroke Trial; MCA, middle cerebral artery; OHS, Oxford 
Handicap Scale; and TICI, Thrombolysis in Cerebral Infarction.
Figure 1. IST-3 (Third International Stroke Trial), ordinal regression analyses, of the effect of alteplase treatment on outcome (Oxford 
Handicap Scale [OHS] as the dependent variable) in patients with more vs less normal results by different angiography features. Results 
represent odds ratio of better (right of vertical line) or worse (left of line) 6-month outcome with alteplase. Adjusted for age, time from 
stroke onset to scan, and stroke severity (National Institutes of Health Stroke Scale). ICA indicates internal carotid artery; MCA, middle 
cerebral artery; and TICI, Thrombolysis in Cerebral Infarction.
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be encouraged because this will facilitate between-trial com-
parisons and meta-analysis.28
Patients recruited in IST-3 after CTA or MRA were random-
ized and treated, on average, 10 minutes later than were those 
with only plain scans. The steep time dependency of alteplase 
effects on outcome means that even this small delay could 
reduce the potential benefit of treatment,29 particularly on a pop-
ulation level if angiography is performed nondiscriminately in 
all ischemic stroke patients. Efforts should be directed at mini-
mizing delays attributable to obtaining angiography in stroke.
Figure 2. IST-3 (Third International Stroke Trial), bar charts comparing Oxford Handicap Scale (OHS) distribution for alteplase and control 
groups in those with (A) and without (B) arterial obstruction. 
Figure 3. Meta-analysis of IST-3 (Third International Stroke Trial), EPITHET (Echoplanar Imaging Thrombolytic Evaluation Trial; alteplase), 
and the DIAS (Desmoteplase in Acute Ischemic Stroke), DIAS-2, and DEDAS (Dose Escalation of Desmoteplase for Acute Ischemic 
Stroke; desmoteplase) trials comparing the effect of intravenous thrombolytics on functional outcome between patients with arterial 
patency vs obstruction. Raw treatment data were unavailable for the Desmoteplase trials. Results represent odds ratio of better (right 
of vertical line) or worse (left of line) outcome after thrombolytics. Open circles represent arterial patency (test for heterogeneity, I2=0%). 
Closed circles represent arterial obstruction (I2=16%). TIMI indicates Thrombolysis in Myocardial Infarction.
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Conclusions
Intravenous thrombolytic therapy is significantly more effec-
tive in improving functional outcome in patients present-
ing with ischemic stroke who have arterial obstruction than 
in those with apparently patent arteries on CTA or MRA. 
Intravenous thrombolytics, therefore, remain an important 
treatment option. The data are too sparse to determine, in this 
analysis, whether patients without apparent arterial obstruc-
tion benefit from intravenous thrombolytics, bearing in mind 
that these patients may have thrombus too small to detect on 
CTA or MRA.
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Table I.  Scoring for angiogram characteristics in IST-3 
 
Imaging Characteristic  Options Presented to Imaging Reader 
Is there an Abnormal/ 
Occluded Artery on CTA/MRA 
Yes 
No 
Location of Angiographic 
Obstruction  
(3 Largest Arteries Selected) 
Internal Carotid Artery (ICA) 
Middle Cerebral Artery (MCA) main stem 
MCA sylvian branch 
Anterior Cerebral Artery (ACA) 
Posterior Cerebral Artery (PCA) 
Vertebral Artery (VA) 
Basilar Artery (BA) 
TICI (Modified)1 
0 = No flow/patency 
1 = Minimal flow/patency 
2a = Partial flow <50% of expected territory 
2b = Partial flow >50% of expected territory 
3 =  Complete flow/patency 
IST-3 Angiography Score2 
(Modified Mori)3 
0 = No patency 
1 = Contrast penetrates obstruction but minimal enters distal artery 
2a = Luminal patency of <50% with partial filling (< half) of major 
branches  
2b = Luminal patency of <50% with partial filling (> half) of major 
branches 
3 = Patency of >50% of lumen and filling of most branches 
4 = Complete patency – normal 
Clot Burden Score4 
(Anterior Circulation Only) 
Six arterial locations are assessed for the presence of clot: 
Infraclinoid (1 point) and supraclinoid ICA (2 points) 
Proximal (2 points) and distal M1 MCA (2 points) 
M2 branches of MCA (1 point each) 
ACA (1 point) 
Collateral Supply (MCA)5 
Good = Entire MCA distal to occlusion fills with contrast 
Moderate = Some of the MCA branches in the sylvian fissure fill with 
contrast 
Poor = Only distal superficial MCA branches fill with contrast  
 
Footnote: 
TICI = Thrombolysis in Cerebral Infarction.   
The coding forms are available at www.sbirc.ed.ac.uk/research/imageanalysis.html 
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Table II.  Clinical characteristics of the patients recruited into IST-3 with angiography compared to the full IST-3 trial. 
 
 
IST-3 Angiography Subgroup 
(n=300) 
Remainder of IST-3 Group 
(n=2735) 
p-value for Difference 
Age (median, IQR) 80 (71-85) years 81 (72-86) years 0.510 
Male Sex (%) 132 (44.0) 1333 (48.7) 0.119 
Time from stroke onset to baseline scan  
(mean, SD) 
180 (80) minutes 162 (71) minutes <0.0001 
Time from stroke onset to randomization 
(mean, SD) 
241 (80) minutes 230 (72) minutes 0.019 
Baseline NIHSS (median, IQR) 9 (5-17) 11 (6-18) 0.003 
Treated with alteplase (%) 147 (49.0) 1368 (50.0) 0.738 
Six-month OHS (median, IQR) 3 (1-5) 4 (2-6) 0.001 
Independent at six-months (OHS 0-2, %) 134 (44.7) 954 (34.9) 0.001 
Dead by six-months (%) 67 (22.3) 748 (27.3) 0.063 
 
Footnote: 
NIHSS = National Institutes of Health Stroke Scale. OHS = Oxford Handicap Scale.  
IQR = Interquartile Range. SD = Standard Deviation. 
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Table III.  Univariate associations between angiography findings, stroke severity and 
outcome in IST-3  
 
Angiography Measure Baseline NIHSS Six-month OHS 
Arterial Obstruction (n=146) 
No Arterial Obstruction (n=154) 
14 (8-20)* 
6 (4-10) 
5 (2-6)* 
2 (1-4) 
Obstructed Arterial Segment Number (n=146) 0.34* 0.37* 
Obstructed Proximal Artery (n=113) 
Obstructed Distal Artery Only (n=29) 
16 (9-21) † 
12 (7-15) 
5 (2-6) ‡ 
3 (1-5) 
IST-3 Angiography Score (n=288) -0.52* -0.34* 
TICI Score (n=288) -0.51* -0.36* 
Clot Burden Score (n=123) -0.45* -0.40* 
Collateral Score (n=135) 0.41* 0.36* 
 
Footnote: 
Numbers represent median (interquartile range) or Spearman’s correlation. 
* p<0.0001, † p=0.023, ‡ p=0.002.  
 
NIHSS = National Institutes of Health Stroke Scale.  OHS = Oxford Handicap Scale.   
TICI = Thrombolysis in Cerebral Infarction.  
 
Proximal arteries include the internal carotid, middle cerebral mainstem, vertebral and basilar 
arteries.  Distal arteries include the sylvian branch of middle cerebral, anterior cerebral and posterior 
cerebral arteries. 
 
Variability in the total patient numbers reflects missing data in some categories; Clot Burden Score 
and Collateral Score was not calculated in all cases.  Not all patients with normal IST-3 angiography 
score had normal TICI score and vice versa.   
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Table IV. Three-way analysis of variance (ANOVA) for interactions between combinations of 
angiographic findings and six-month OHS in IST-3 
 
Angiographic Finding Combination Degrees of Freedom F p-value 
Clot Burden Score * TICI 18 1.306 0.217 
Clot Burden Score * Collateral Score 9 1.480 0.176 
TICI * Collateral Score 6 1.416 0.223 
Clot Burden Score * TICI * Collateral Score 6 0.814 0.564 
 
Footnote: 
Due to collinearity between some of the angiographic measures, only one feature assessing extent 
of obstruction (Clot Burden Score rather than arterial segment number) and one feature assessing 
completeness of obstruction (TICI rather than IST-3 angiography score) were included in this ANOVA 
based on the strength of their associations with OHS on univariate analysis (Table III). There was also 
strong collinearity between location and extent of obstruction with very few multi-segment 
obstructions sited distally rather than proximally; location of obstruction was therefore also 
excluded from this ANOVA. 
OHS = Oxford Handicap Scale.  TICI = Thrombolysis in Cerebral Infarction.   
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Figure I.  PRISMA flow diagram demonstrating the identification and selection of trials for 
inclusion in the meta-analysis 
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Figure II.  Meta-analysis of IST-3 and EPITHET comparing the effect of alteplase on outcome between patients with ICA versus MCA obstruction 
 
 
Footnote: 
Total patient numbers in each trial are provided, n. 
 
Results represent odds ratio (95% confidence interval).  
Vertical line represents an odds ratio = 1, i.e. no treatment effect on outcome.  Left of the line indicates a worse outcome, right of the line a better outcome 
following alteplase. 
 
EPITHET = Echoplanar Imaging Thrombolytic Evaluation Trial.7 
ICA = Internal Carotid Artery (test for heterogeneity, I2 = 74 %).  MCA = Middle Cerebral Artery (I2 = 0%).  
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Appendix I. IST-3 Collaborative Group 
 
For a complete list of all committees, please see the IST-3 primary publication in The Lancet (The 
benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator 
within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomized 
controlled trial. Lancet 2012;379:2352-63). 
 
CO-INVESTIGATORS 
 
Peter Sandercock, DM (University of Edinburgh, Scotland, co-chief Investigator); Richard I Lindley, 
MD (Sydney Medical School – Westmead Hospital and The George Institute for Global Health, 
University of Sydney, Australia, co-chief Investigator); and Joanna M Wardlaw, MD (University of 
Edinburgh, Scotland, co-chief Investigator for neuroradiology). 
 
CONTRIBUTORS 
 
Trial Steering Committee 
Colin Baigent (University of Oxford, UK, independent chairman); David Chadwick (University of 
Liverpool, UK, independent chairman); Pippa Tyrrell (University of Manchester, UK, independent 
member); Gordon Lowe (University of Glasgow, UK, independent member); Martin Dennis 
(University of Edinburgh, Scotland); Geoff Cohen (University of Edinburgh, Scotland, statistician); 
Karen Innes (University of Edinburgh, Scotland, trial coordinator); Heather Goodare (lay 
representative). 
 
National coordinators and associate national coordinators 
Australia: Richard I Lindley, MD (Sydney Medical School – Westmead Hospital and The George 
Institute for Global Health, University of Sydney, Australia); Graeme J Hankey (Royal Perth Hospital, 
Perth). Austria: Karl Matz (Landesklinikum Donauregion Tulln, Tulln), Michael Brainin. Belgium: AP. 
Canada: Gord Gubitz (Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax), 
Stephen J Phillips (Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax). Italy: 
Stefano Ricci (Department of Neurology ASL1, Ospedale, Citta’ di Castello). Mexico: Antonio Arauz 
(Instituto Nacional de Neurologia, Mexico City). Norway: Eivind Berge (Oslo University Hospital, 
Oslo), Karsten Bruins Slot (Oslo University Hospital, Oslo). Poland: Anna Czlonkowska (Institute of 
Psychiatry and Neurology, Warsaw, and Medical University of Warsaw, Warsaw), Adam Kobayashi 
(Institute of Psychiatry and Neurology, Warsaw, Poland). Portugal: Manuel Correia (Hospital Geral de 
Santo Antonio, Porto). Switzerland: Phillippe Lyrer (University Hospital Basel, Basel), Stefan Engelter. 
Sweden: Veronica Murray (Karolinska Institutet, Stockholm), Andreas Terent, Bo Norrving, Per 
Wester: UK: Graham Venables (Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK). 
 
CT and MRI reading panel 
Joanna M Wardlaw, Andrew Farrall (University of Edinburgh, Scotland), Zoe Morris (University of 
Edinburgh, Scotland), Rüdiger von Kummer (Dresden University Stroke Centre, Germany), Lesley Cala 
(University of Western Australia, Crawley, Australia), Anders von Heijne (Dandyred Hospital, 
Stockholm, Sweden ), Alessandro Adami (Sacro Cuore-Don Calabria Hospital, Verona, Italy), Andre 
Peeters (Cliniques Universitaires Saint-Luc, Bruxelles, Belgium), Gillian Potter (Salford Royal NHS 
Foundation Trust, England), Nick Bradey (Neuroradiology, James Cook University Hospital, South 
Tees Hospital NHS Trust, Middlesborough, UK). 
 
Angiography reading panel 
Joanna M Wardlaw, Rüdiger von Kummer, Andrew Farrall, Robin Sellar (University of Edinburgh, 
Scotland), Alessandro Adami, Philip White (Newcastle University, UK), Andrew Demchuk (University 
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of Calgary, Canada), Matthew Adams (Great Ormond Street Hospital, London, UK), Grant Mair 
(University of Edinburgh, Scotland), Bernard Yan (The Royal Melbourne Hospital, Parkville, Australia). 
 
IST-3 collaborative group and participating hospitals in each country  
Figures in parentheses are the number of patients recruited in the country or by the centre.  
 
UK (1447) Royal Hallamshire Hospital (118): G Venables, C Blank, H Bowler, C Doyle, K Endean, K 
Harkness, E Parker, M Randall. University Hospital of North Staffordshire (97): C Roffe, N Ahmad, A 
Arora, S Brammer, J Chembala, B Davies, S Ellis, E Epstein, K Finney, C Jackson, C Jadun, R Kinston, H 
Maguire, I Memon, I Natarajan, M Poulson, R Sanyal, S Sills, A Vreeburg, E Ward. Western General 
Hospital (95): P Sandercock, R Al-Shahi Salman, R Davenport, M Dennis, P Hand, S Hart, I Kane, S 
Keir, M MacLeod, L McKinlay, H Milligan, E Sandeman, J Stone, C Sudlow, P Taylor, J Wardlaw, C 
Warlow, W Whiteley, A Williams. The National Hospital for Neurology & Neurosurgery (84): M 
Brown, B Athwal, V Bassan, N Bhupathiraju, J Bowler, C Davie, D Doig, R Erande, S Gilbert, L 
Ginsberg, R Greenwood, S Gregoire, N Harding, N Losseff, R Luder, N Passeron, R Perry, P Rayson, R 
Simister, S Stone, D Werring. Arrowe Park Hospital (83): J Barrett, H Aitken, S Cherian, R Davis, S 
Downham, L Godd, V Gott, D Jose, V Little, D Lowe, L Luxford, M McGrory, P Owings, N Price, J 
Richards, G Sangster, J Sherlock, S Vargese, I Wakefield, P Weir. Southend University Hospital (77): P 
Guyler, T Attygale, S Chandler, L Coward, S Feasey, C Khuoge, T Loganathan, S Martin, A O'Brien, D 
Sinha, V Thompson, S Tysoe, R Walsh. Norfolk and Norwich University Hospital (67): K Metcalf, J 
Cochius, R Fulcher, N Gange, C Green, J Jagger, M Lee, P Myint, J Potter, G Ravenhill, S Shields, N 
Shinh, T Staunton, E Thomas, W Woodward, P Worth, N Wyatt. Nottingham City Hospital (63): W 
Sunman, P Bath, P Berman, J Clarke, C Gaynor, F Hammonds, R Harwood, K Mitchell, S Munshi, S 
Pacey, A Shetty, N Sprigg, H Stear, G Subramanian, A Wills. Guy's & St.Thomas Hospital (60): A Rudd, 
H Audebert, A Bhalla, J Birns, R Chowdhury, G Cluckie, I Davies, C Gibbs, P Holmes, N Mitchell, F 
Schiavone, E White, M Yeung. Darlington and Bishop Auckland Hospitals (56): A Mehrzad, V Baliga, E 
Brown, L Burnside, B Esisi, J Kent, P Orr, D Stead, E Wayman. University Hospital Aintree (46): R 
Durairaj, C Cullen, R Kumar, H Martin, D McDowell, A Sharma, V Sutton, R White. University Hospital 
of Wales (46): T Hughes, K Ali, J Anderson, K Baker, K Bethune, K Bethune, M Booth, M Cossburn, S 
Halpin, M Hourihan, E Marsh, K Peall, R Powell, H Shetty, M Wardle, M Williams. Derby Royal 
Hospital (37): K Muhiddin, J Beavan, M Clarke, R Donneley, S Elliott, P Fox, P Gorman, M Harper, M 
Mangoyana, I Memon, L Mills, L Wright. Addenbrookes Hospital (34): L Warburton, J Baron, P Barry, 
D Day, T Harold, P Martin, J Mitchell, E O'Brien, J Rycarte, M Turnham. St George's Healthcare NHS 
Trust (34): G Cloud, L Choy, B Clarke, C Griffin, O Halse, I Jones, F Kennedy, U Khan, R Lewis, A 
Loosemore, C Lovelock, H Markus, B Moynihan, J O'Reilly, O Paul, A Pereira, M Punter, P Rich, D 
Rolfe, F Schiavone. Royal Devon & Exeter Hospital (Wonford) (30): M James, J Bell, A Bowring, L 
Boxall, J Cageao, H Eastwood, S Elyas, F Hall, S Harries, A Hemsley, S Jackson, S Keenan, P Mudd, A 
Sekhar, D Strain, J Sword, N Wedge. Aberdeen Royal Infirmary (26): M MacLeod, M Bruce, A Joyson, 
M Kemp, K McMullan, J Reid, O Robb, J Webster, S Wilkinson. Hammersmith Hospitals & Imperial 
College (24): P Sharma, P Bentley, H Jenkins, A Kar, T Sachs. Northwick Park Hospital (20): D Cohen, R 
Bathula, J Devine, M Mpelembue. William Harvey Hospital (20): D Hargroves, I Balogun, L Cowie, A 
Maidment, D Rand, J Rowe, H Rudenko, D Smithard, L Wray. Scarborough Hospital (17): J Paterson, J 
Brown, J Hampton, S Jamieson, R Rose, A Volans. Countess of Chester Hospital NHS Foundation Trust 
(17): K Chatterjee, G Abbott, R Brookes, C Castle, C Kelly, S Leason, A Nallasivan, A Sen. Watford 
General Hospital (17): D Collas, M Cottle, N Damani, P Jacob, D Oza, D Werring. University Hospitals 
Coventry & Warwickshire NHS Trust (15): A Kenton, N Adab, L Aldridge, H Allroggen, Y Brown, R 
Cross, L Galvin, K Ghosh, A Grubneac, A Lindahl, H Mehta, M Pritchard, C Randall, P Ray, A Shehu, S 
Thelwell. Royal Bournemouth & Christchurch NHS Trust (12): D Jenkinson, J Bell, T Black, O David, J 
Kwan, A Orpen, C Ovington, D Tiwari, Z ud Din Babar. Leeds General Infirmary (12): A Hassan, A 
Bailey, J Bamford, C Bedford, R Bellfield, J Cooper, L Dunsmure, J Greig, M Keeling, L Mandizvidza, J 
Rankine, E Roberts, P Wanklyn, T Webb, S Williamson. York Health Services NHS Trust (12): J Coyle, S 
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Crane, C Croser, P Duffey, R Evans, E Iveson, M Keeling, G Kitching, M Porte, C Rhymes. Queen 
Elizabeth Hospital (Gateshead) (12): D Barer, M Armstrong, M Bokhari, T Cassidy, B 
McClelland. Queen Elizabeth The Queen Mother Hospital (10): G Gunathilagan, P DOLKE, S Jain, S 
Jones, A Maidment, L Rosser, G Thomas, C White. Worcestershire Royal Hospital (10): P 
Sanmuganathan, C Scholtz, E Stratford. Blackpool Victoria Hospital (10): M O'Donnell, H Goddard, G 
Hoadley, J Howard, S Leach, J McIlmoyle, A Stewart, A Strain. Basildon & Thurrock University 
Hospitals NHS FT (9): F Huwez, P Croot, N Gadi, N Mguni, U Umasankar. Royal Infirmary of Edinburgh 
(8): G Mead, B Chapman, A Coull, S Hart, A Kinnear, B Morrow, F Morrow. St Mary's Hospital (8): D 
Ames, J Ball, S Bannerjee, J Chataway. Yeovil District Hospital (8): K Rashed, C Buckley, D Donaldson, 
D Hayward, C Lawson. Luton and Dunstable Hospital (8): L Sekaran, K Bharaj, F Justin, G Jutlla, D 
Phiri, S Sethuraman, M Tate. Solihull Hospital, Heart of England NHS Trust (8): D Sandler, P Carr, G 
Jones, J Lyons, K Warren. King's College Hospital (7): L Kalra, A Davis, J Jarosz, D Manawadu, L 
Sztriha. Doncaster Royal Infirmary (7): D Chadha, A Holford, P Willcoxson. Royal United Hospital Bath 
(7): L Shaw, D Button, A Cunningham, L Dow, J Dutson, T Hall, C Hardy, N Jakeman, P Kaye, B 
Madigan, K O'Brien, D Pressdee, M Price, L Robinson, C Taylor, D Williamson. Birmingham Heartlands 
Hospital (6): D Sandler, P Carr, J Lyons, J McCormack, C Stretton. University Hospital North Durham 
(6): P Earnshaw, E Brown, S Bruce, C Church, S Desai, B Esisi, M Myint, N Watt. Wansbeck General 
Hospital (6): C Price, S Elliott, H Graham, R Lakey, K Mitchelson. Bristol Royal Infirmary (6): P Murphy, 
L Ball, S Caine, J Dovey, J Hughes, A Steele. Stepping Hill Hospital (6): K Dizayee, A Brown, T 
Chattopadhyay, J Cheetham, H Cochrane, A Datta, M Datta-chaudhuri, C Fox, D Kilroy, S 
Krishnamoorthy, F Levy, S Metha, P Ngoma, B Venkatesh. Princess Royal Hospital Brighton & Sussex 
University Hospitals Trust (5): K Ali, R Gautam, N Henderson, M Jones, S Murphy, G Spurling. Belfast 
City Hospital (5): I Wiggam, C Boyd, K Fullerton, P Gray, M Kinnaird, S MacNair, C Morgan, M Reid, S 
Tauro. Royal Liverpool University Hospital (5): S Loharuka, D Balmforth, P Cox, G Fletcher, A Ledger, 
A Manoj, M Wilkinson. City Hospital, Sandwell & West Birmingham Hospital (5): D Nicholl, S Clegg, S 
Hurdowar, S Kausar, K Law, A Singal, S Sturman. Royal London Hospital (4): P Gompertz, J Evanson, A 
Farrell, A Petrou, K Saastamoinen, T Sachs, A Salek-Haddadi, R Yadava. Sunderland Royal Hospital (4): 
J O'Connell, H Brew, S Butler, S Crawford, C Gray, D Gulliver, N Majmudar, R O'Brien. Morriston 
Hospital (4): M Wani, L Dacey, L Davies, R Evans, D Harris, T Jones, S Storton. Royal Preston Hospital 
(4): S Punekar, A Ashton, S Duberley, H Emsley, C Gilmour, B Gregary, L Hough, S Philip, S 
Wuppalapati. The Royal Wolverhampton Hospitals NHS Trust (4): K Fotherby, P Bourke, D D'Costa, K 
Kauldhar, D Leung, R Lodwick, S McBride, D Morgan, M Qaiyum, G Sahota, M Srinvasan. Royal West 
Sussex NHS Trust, St Richard's Hospital (4): I Kane, N Chuter, L Garrad, M Hookway, S Ivatts, G 
Kennedy. Queen's Hospital Romford (4): K Darawil, L Al Dhahirl, S Andole, M Baig, P Dugh, K Dunne, 
H Kariuki, M Khan, S Rathnayaka. Ulster Hospital (3): M Power, K Dynan, J Finnerty, A Heaney, C 
Leonard, K McKnight, J Turkington, B Wroath. Great Western Hospital (3): B Dewan, S Cotton, M 
Gardiner, T Saunders, B Vincent. The Queen Elizabeth Hospital Birmingham (3): D Sims, P Guest, E 
Jones, J McCormack, D Nicholl, J Savanhu, R Tongue, M Willmot. Leicester General Hospital (3): D 
Eveson, S Dawson, M Dickens, M Fotherby, R Hunt, S Khan, T Kumar, R Marsh, A Mistri, T Robinson, J 
Thompson. Darent Valley Hospital, Dartford & Gravesham NHS Trust (3): P Aghoram, T Daniel, M 
Gatehouse, S Hussein, A Jackson, T Shanganya, E Strachan, G Tan. Nevill Hall Hospital, Aneurin Bevan 
Local Health (3): B Richard, S Elaine, S Hanson, S Mosely, H Reed, M Williams. Colchester Hospital 
University Foundation Trust (3): R Saksena, S Cook, D Demuran, M Keating, R Needle, V Paramsothy, 
A Sebastian, R Sivakumar, A Wright. Salford Royal Hospital Foundation NHS Trust (2): R Grue, E 
Barberan, C Dickson, C Douglas, J Jellicoe, T Marsden, J Priestley, E Quick, C Sherrington, A Singh, C 
Smith, J Stevens, P Tyrell, J Wainwright. Leicester Royal Infirmary (2): M Ardron, J Birchall. Queen 
Elizabeth Hospital (Kings Lynn) (2): R Shekhar, C Barsted, S Coleman, S Fletcher, J Graham. John 
Radcliffe Hospital (2): A Buchan, J Hinkle, J Kennedy, A Manoj, M Westwood. Derriford Hospital (2): A 
Mohd Nor, S Allder, B Hyams, A Pace. West Cumberland Hospital (1): E Orugun, C Brewer, L Huntley, 
R Jolly, C Summers. Sandwell General Hospital (1): K Sharobeem, J Khaira, J Leahy, E Linehan, G 
Moore, J Rizkalla, J Wilkinson. Torbay Hospital (1): D Kelly, C Hilaire. Warrington & Halton Hospitals 
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NHS Foundation Trust (1): O Otaiku, L Connell, G Delaney-Sagar, G James, L Lomax, D Matthew, J 
Simpson, H Whittle. Medway Maritime Hospital (1): S Sanmuganathan, S Burrows, A 
Mahmood. Southampton General Hospital (1): G Durward, S Barker, J Cantle, P Crawford, S Evans, V 
Pressly, N Weir. Victoria Hospital (1): V Cvoro, K McCormick. Poland (347) 2nd Department of 
Neurology, Institute of Psychiatry & Neurology (190): A Czlonkowska, J Bembenek, M Bilik, G Chabik, 
W Czepiel, J Dzierka, M Gluszkiewicz, K Grabska, B Janus-Laszuk, J Jedrzejewska, A Kobayashi, T 
Litwin, A Oskedra, A Piorkowska, M Skowronska, A Sliwinska, U Stepien. SPZZOZ w Sandomierzu (43): 
P Sobolewski, A Gajewska, M Grzesik, R Hatalska-Zerebiec, I Labudzka, B Loch, A Medrykowska, M 
Sledzinska, A Sobota, W Szczuchniak, G Wolak, I Zdyb. Medical University of Gdansk (35): W Nyka, D 
Gasecki, K Chwojnicki, A Gojska, B Karaszewski, G Kozera, M Kwarciany, M Nowak, M Swierkocka-
Miastkowska , S Szczyrba, M Wisniewska, E Wnorowska. 1st Department of Neurologyt, Institute of 
Psychiatry & Neurology (25): P Richter, A Bochynska, M Chahwan, A Graban, R Rola. Military Medical 
Institute (24): A Stepien, B Brodacki, M Grotowska, J Kotowicz, J Staszewski, J Swistak, S 
Zaloga. Szpital Powiatowy (14): J Stoiñski, K Czajkowaka-Fornal, P Czubak, A Kaczor, J Kraska, E 
Nowakowska-Sledz, J Ozdoba-Rot, E Zawadzka. Szpital Specjalistyczny w Konskich (8): M Fudala, D 
Adamczyk, W Brola, I Guldzinska, K Kaluzny, M Kucharska-Lipowska, M Mosiolek, M Polewczyk, M 
Ziomek. Central University Hospital (7): G Opala, M Arkuszewski, M Kudlacik, P Malgorzata, M 
Swiat. SPSK im. Prof. W. Orlowskiego CMKP (1): U Fiszer, M Lenska-Mieciek. Italy (326) Ospedale Di 
Citta' di Castello (62): S Cenciarelli, A Barilaro, R Condurso, F Coppola, S Dioguardi, E Gallinella, A 
Mattioni, C Menichetti, S Ricci. Nuovo Ospedale Civile "S.Agostino-Estense" (40): F Casoni, M 
Bacchelli, M Cavazzuti, M Malagoli, A Zini. Ospedale Beato Giacomo Villa - Citta' della Pieve (36): G 
Benemio, M Celani, R Allegrucci, V Bondo, S Cupella, L Guerra, S Guerrieri, C Ottaviani, E Righetti, C 
Rossi, N Sacchi, M Scucchi, V Stefanini. Ospedale Di Branca (36): T Mazzoli, A Bigaroni, L Greco, R 
Paris, P Parise, S Ricci. A.O. Niguarda Ca'Granda (25): A Ciccone, L Basso, R Causarano, P Doneda, E 
Ferrante, A Gatti, A Guccione, A Gullo, F Imbesi, S Jann, R Marazzi, E Moro, C Motto, D Parodi , A 
Protti, M Riva, A Rosiello, I Santilli, R Sterzi, P Tiraboschi, G Venturelli. R.Guzzardi Hospital - Vittoria 
(RG) (19): F Iemolo, R Campagna, G Campagnolo, A Carnemolla, N D'Apico, G D'Asta, S Giannarita, A 
Giordano, E Sanzar. Ospedale Regionale di Aosta (17): E Bottacchi, S Cordera, G Corso, M Di 
Giovanni, G Giardini, C Lia, T Meloni, M Pesenti Campagnoni, P Tosi. Ospedale Sacro Cuore - Negrar 
Verona (12): A Adami, G Rossato, T Zuppini. Ospedale Maggiore - Bologna (12): G Procaccianti, T 
Sacquegna. Universita degli Studi di Genova (11): C Gandolfo, M Balestrino, C Bruno, L Castellan, M 
Del Sette, A Ferrari, C Finocchi, N Reale, D Rizzi. Ospedale Civlle S.Andrea (9): M Del Sette, L 
Benedetti, C Capellini, E Carabelli, E Cibei, M Godani, G Guariglia, E Landini, A Mannironi, B 
Nucciarone, S Parodi, S Tonelli, E Traverso, D Zito. Ospedale S. Giovanni Battista - Foligno (8): P 
Brustenghi, F Corea, O Flamini, S Lolli, G Pelliccia, R Ricci, S Stefanucci, M Zampolini. Ospedale a Vibo 
Valentia (8): D Consoli, F Galati, P Postorino. Azienda Ospedaliero-Universitaria "Ospedali Riuniti" di 
Foggia (8): G Rinaldi, E Carapelle, G Grilli, M Guido, L Specchio. Ospedale Valduce di Como (8): N 
Checcarelli, G Borin, L Chiveri, R Clerici, E Corengia, L Gandola, P Garavaglia, M Guidotti, A 
Martegani, M Mauri, F Muscia, F Raudino. Ospedale di Cattinara - Trieste (4): F Chiodo Grandi, A 
Bratina, N Carraro, M Gaio, A Granato, N Koscica, M Naccarato, V Sarra, P Schincariol, C Vilotti, Z 
Zugna. Clinica Dr Pederzoli Spa (4): D Idone, C Bonato, E De Angelis, A Forgione, M Gambera, F 
Recchia, S Tamburin, P Tinazzi Martini, G Zanette. Ospedale Civile San Matteo Degli Infermi - Spoleto 
(2): S Grasselli. Ospedale Silvestrini - Perugia (2): G Agnelli, A Andrea, A Billecia, V Caso, V Casso, R 
Fabiola, P Fanelli, M Paciaroni, B Sergio, M Vemti. Mater Salutis Hospital, Legnago VR (2): M Silvestri, 
L Altarini, A Bonfante, M Bonornetti, B Costa, N D'Attoma, N Deluca, F Frattini, R Niego, D Rafaele, V 
Ravenna, M Turazzini. Ospedale Guglielmo da Saliceto - Piacenza (1): S Cammarata. Sweden (297) 
Uppsala University Hospital (100): E Lundström, L Jonsson , U Söderström, A Terént. Danderyd 
Hospital (46): V Murray, A Alvelius, M Arbin von, I Dalenbring, Å Doverhall, Å Franzén-Dahlin, N 
Greilert, M Hallberg, A Heijne von, E Isaksson, H Kumpulainen, A Laska, A Lundström, C Martin, J 
Muhrbeck, E Näslund, N Ringart, E Rooth, R Undén, P Waldenström. Hassleholm Hospital (29): M 
Esbjornsson, M Petranek. Karnsjukhuset (25): B Cederin, E Bertholds, A Elgåsen, T Johansson, B 
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Witteborn. Koping Hospital (20): M Kwiatkowska, E Gustafsson, T Noren, J Saaf. Mora Hospital (17): J 
Teichert, M Bertilsson, S Nilsson, S Oestberg. LidkopingHospital (11): L Welin, K Fredricson, L 
Pehn. Falu Hospital (11): J Hambraeus, I Lonn. Capio S: tGoran Hospital (9): B Hojeberg, A Adolfsson, 
M Anzen. Vastervik Hospital (5): T Wallen, R Schloenzig, P Söderström, A Wennerberg. University 
Hospital MAS (5): F Buchwald, K Abul-Kasim, A Berkeskold, J Petersson, E Poromaa. University 
Hospital of Northern Sweden (4): P Wester, R Backlund, A Sjöström. Helsingborgs lasarett (4): B 
Hedström , E Campbell, K Johnsson, B Karlsson, N Lekokotla, C Lundahl, A Risedal, P Sandgren, A 
Svensson. Visby Hospital (4): S Bysell, E Smedberg, A Vestberg Bysell. Sundsvall Hospital (3): V 
Sjögren, B Högvall. University Hospital Lund (2): G Andsberg, T Cronberg, A Lindgren. Vasteras 
Hospital (1): H Wannberg, F Ax, L Nyren. Karlstad Central Hospital (1): J Sanner, H Andersson, F 
Andler, S Holmgård, R Johansson, I Magnussan, K Nilsson, J Rådberg. Norway (204) Trondheim 
University Hospital (69): B Indredavik, H Ellekjær, A Østvik, G Rohweder, D Steckhan, J Storvold. Oslo 
University Hospital Sykehus (66): E Berge, Y Rønning, R Aakvik, K Bruins Slot, G Knutsen, M Moxness, 
R Pettersen, T Wyller. University Hospital of North Norway (23): C Wahl, O Iversen, S Johnsen, B 
Norderhus, L Steffensen, E Stensland. Kongsvinger Hospital (13): T Asak, J Aaseth, T Rotnes, J Sparby, 
S Wetterhus. Levanger Hospital (9): H Hallan, A Aardal, T Graven, H Hansbakk Skjetne, B Klykken, K 
Lindqvist, A Tommy. University Hospital of North Norway (8): T Engstad, M Antonsen, R Bajic, W 
Fønnebø, S Hykkerud, I Lyngmo, A Nyrnes, S Rogne, S Sparr. Harstad Hospital (7): O Kildahl-
Andersen, K Pedersen, H Ulrichsen. Ålesund Hospital (4): O Skogen, I Alnes, R Hukari, Y Seljeseth, P 
Vadset.  Asker and Bærum Hospital (2): G Knutsen, B Fure, H Ihle-Hansen, N Johnsen, L 
Kornberg. Namsos Hospital (2): S Schuler, M Heibert. Volda Hospital (1): M Lillebø, O Aasen, I 
Eskeland, T Hamre, S Hareide, H Helset, K Kolnes, B Lødemel, H Ose Velle, S Reite, E Velle. Australia 
(179) Nambour General Hospital (51): R Grimley, E Ahern, C Cocks, M Courtney, R Devin, J Endacott , 
C Fawcett , V Harrington, C Johnston, M Koltermann, S Murray, K Ng, G Styles, A Tampiyappa. John 
Hunter Hospital (29): C Levi, K Chung, L Dark, M Evans, Y Gawarikar, E Kerr, A Loiselle, F Miteff, A 
Moore, W O'Brien, M Parsons, D Quain, A Royan, M Russell, N Spratt. Gosford Hospital (24): J Sturm, 
D Crimmins, D Griffiths, P Kavelieros, J Kinsella, A Malhotra, B O'Brien, A Schutz, M Webb, S Whyte, V 
Zenteno. Westmead Hospital (16): R Lindley, A Bleasel, N Cordato, A Duggins, V Fung, L Gomes, N 
Ingham, J Ip, P Landau, J Morris, S Vucic. Royal Perth Hospital (15): G Hankey, A Claxton, N 
Lillywhite. The Canberra Hospital (12): C Lueck, C Andrews, G Danta, C Das, I Harvey, A Hughes, C 
McColl, A Oon, R Tuck. Royal Brisbane and Women's Hospital (10): S Read, M Badve , M Broad, G 
Cadigan, H Cavanagh, J Chalk, D Copsinis, K Etherington, R Henderson, R Hull, J O'Sullivan, J Pandian, 
L Ross-Lee, M Roxas, N Sheikh, G Skinner, A Wong. Austin Health - Repatriation Campus (8): H 
Dewey, A Brodtmann, G Donnan, A Hughes, M Karonen, H Ma, T Mulcahy, S Petrolo, L Walker, D 
Young, J Zavala. Nepean Hospital (7): M Thieben, C Harris, M Krause, S Lane, H Park, M Shaffi, J 
Wood. Box Hill Hospital (7): C Bladin, A Buckland, K Coughlan, B Coulton, A Gilligan, P Lee, S Mullen, 
Z Ross, P Sien Loh, C Szoeke. Portugal (82) UAVC. Centro Hospitalar de Trás-os-Montes e Alto Douro 
(42): M Silva, F Afonso, J Gabriel, P Guimarães, A Velon. Hospital Pero da Covilhã (19): M Castelo- 
Branco, F Alvarez, V Branco, C Coxo, P Goulao, D Leal, S Morgado, R Oliveira, F Paiva, A Rodrigues, M 
Simoes. Hospital de Santo António (12): G Lopes, T Almeida, M Cardoso, J Chaves, C Correia, M 
Correia, J Damásio, R Felgueiras, J Pereira, A Tuna. Hospital S.Marcos (9): C Ferreira, E Lourenco, A 
Machado, R Mare, J Rocha. Belgium (73) Cliniques Universitaires St Luc (73): A Peeters. Austria (46) 
Landesklinikum Donauregion Tulln (34): K Matz, M Brainin, G Funk, V Reiner-
Deitemyer. Krankenhaus Der Barmherzigen Bruder Wien (9): J Ferrari, A Flamm-Horak, G Gruber, R 
Rattinger. Krankenhaus Göttlicher Heiland (3): W Muellbacher, D Doppelbauer, R Kalchmayr, W 
Schima, T Wieser, M Zart. Switzerland (23) Universitatsspital Basel (22): P Lyrer, L Bonati, S Engelter, 
F Fluri, S Muller, E Radue, A Tiemessen, L Walz, F Weisskopf, S Wetzel. Universitätsspital Zürich (1): A 
Luft, D Fetz, B Hertler, A Pangalu. Canada (8) QEII Health Sciences Centre (8): G Gubitz, P Boulton, J 
Jarrett, J Moeller, S Phillips. Mexico (3) Instituto Nacional de Neurologia y Neurojrugia MVS (3): A 
Arauz, L Bermudez, J Calleja, R Garcia.  
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Appendix II. PRISMA 2009 checklist for meta-analysis8 
 
Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.   
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, 
and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; 
systematic review registration number.  
iii 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  1 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, 
and study design (PICOS).  
2 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration 
information including registration number.  
 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, 
publication status) used as criteria for eligibility, giving rationale.  
 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) 
in the search and date last searched.  
6 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.   
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the 
meta-analysis).  
6 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining 
and confirming data from investigators.  
6 
Data items  11 List and define all variables for which data were sought and any assumptions and simplifications made.  6 
Risk of bias in individual studies  12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the 
study or outcome level), and how this information is to be used in any data synthesis.  
 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  6 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for 6 
13 
 
each meta-analysis.  
 
Section/topic  # Checklist item  
Reported 
on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within 
studies).  
 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were 
pre-specified.  
 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, 
ideally with a flow diagram.  
9, Figure I 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the 
citations.  
9, Figures 
3 & II 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).   
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) 
effect estimates and confidence intervals, ideally with a forest plot.  
Figures 3 
& II 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  9 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).   
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).   
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups 
(e.g., healthcare providers, users, and policy makers).  
10 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified 
research, reporting bias).  
12 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  13 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic 
review.  
14 
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Appendix III. Centres that provided baseline CT or MR angiography in IST-3 
 
Angiography data for the 300 cases used in these analyses came from the following Principle 
Investigators at their respective centres (n): 
 
Prof Martin Brown, The National Hospital for Neurology & Neurosurgery, London, UK (68); 
Prof Anna Czlonkowska, 2nd Department of Neurology, Institute of Psychiatry & Neurology, 
Warsaw, Poland (30); Dr Erik Lundström, Uppsala University Hospital, Sweden (24); Dr Andre 
Peeters, Cliniques Universitaires St. Luc, Brussels, Belgium (20); Prof Philippe Lyrer, 
Universitätsspital Basel, Switzerland (18); Dr Jonathan Sturm, Gosford Hospital, Australia 
(13); Prof Christine Roffe, University Hospital of North Staffordshire, Stoke-on-Trent, UK 
(12); Dr Chris Levi, John Hunter Hospital, Newcastle, Australia (12); Dr Gaetano Procaccianti, 
Ospedale Maggiore, Milan, Italy (11); Dr Federica Casoni, Nuovo Ospedale Civile, Modena, 
Italy (11); Dr Stein Harald Johnsen, University Hospital Northern Norway (10); Dr Magnus 
Esbjornsson, Hassleholm Hospital, Sweden (10); Dr Bent Indredavik, St Olavs Hospital, 
University Hospital of Trondheim, Norway (9); Dr Karl Matz, Landesklinikum Donauregion 
Tulln, Austria (8); Dr David Hargroves, William Harvey Hospital, Ashford, UK (7); Dr Pankaj 
Sharma, Hammersmith Hospitals & Imperial College, London, UK (7); Prof Peter Sandercock, 
Western General Hospital, Edinburgh, UK (5); Dr Eivind Berge, Ullevål University Hospital, 
Oslo, Norway (3); Dr Patrick Gompertz, The Royal London Hospital, Barts and The London 
NHS Trust, UK (3); Professor Chris Bladin, Box Hill Hospital (Monash University), Australia (3); 
Dr Liz Warburton, Addenbrooke’s Hospital, Cambridge, UK (2); Dr Stephen Read, Royal 
Brisbane and Women's Hospital, Australia (2); Dr Fabio Chiodo Grande, Ospedale di 
Cattinara, Trieste, Italy (1); Prof Graeme Hankey, Royal Perth Hospital, Australia (1); Prof 
Lalit Kalra, King’s College Hospital, London, UK (1); Dr Gunaratnam Gunathilagan, Queen 
Elizabeth the Queen Mother Hospital, Margate, UK (1); Dr Odd Kildahl-Andersen, Harstad 
Sykehus, Norway (1); Prof Walenty Michal Nyka, Dr Dariusz Gasecki, Medical University of 
Gdansk, Poland (1); Dr Yngve Müller Seljeseth, Aalesund Sjukehus, Norway (1); Prof Per 
Wester, University Hospital of Northern Sweden (1); Prof Carlo Gandolfo, Universita degli 
Studi di Genova, Dipartimento di Neuroscienze Oftalmologia e Genetica, Italy (1); Dr Paul 
Guyler, Southend University Hospital, Westcliff-on-Sea, UK (1); Dr David Nicholl, City 
Hospital, Sandwell & West Birmingham Hospitals NHS Trust, UK (1); Prof Andreas Luft, 
Universitätsspital Zürich, Switzerland (1). 
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Appendix IV. Funding sources for IST-3 
 
The start-up phase of IST-3 was supported by a grant from the Stroke Association, UK (TSA 
04/99). The expansion phase was funded by the Health Foundation UK (2268/1282). The scan 
reading development was funded by Chest, Heart Stroke Scotland (R100/7).  
 
The main phase of the trial is funded by: UK Medical Research Council (MRC) (grant numbers 
G0400069 and EME 09-800-15) and managed by the National Institute for Health Research 
(NIHR) on behalf of the MRC-NIHR partnership; the Research Council of Norway; 
Arbetsmarknadens Partners Forsakringsbolag (AFA) Insurances Sweden; the Swedish Heart 
Lung Fund; The Foundation of Marianne and Marcus Wallenberg, Stockholm County Council; 
Karolinska Institute Joint ALF-project grants Sweden, the Polish Ministry of Science and 
Education (grant number 2PO5B10928); the Australian Heart Foundation; Australian National 
Health and Medical Research Council (NHMRC);  the Swiss National Research Foundation; the 
Swiss Heart Foundation; the Foundation for Health and Cardio-/Neurovascular Research, Basel, 
Switzerland; the Assessorato alla Sanita, Regione dell'Umbria, Italy; and,  Danube University, 
Krems, Austria.  
 
Boehringer-Ingelheim GmbH donated drug and placebo for the 300 patients in the double-
blind phase, but thereafter had no role whatsoever in the trial.   
 
The UK Stroke Research Network (SRN study ID 2135) adopted the trial in 01/05/2006, 
supported the initiation of new UK sites, and in some centres, and, after that date, data 
collection was undertaken by staff funded by the network or working for associated NHS 
(National Health Service) organisations.   
 
IST-3 gratefully acknowledges the extensive support of the NIHR Stroke Research Network, 
NHS Research Scotland (NRS), through the Scottish Stroke Research Network, and the National 
Institute for Social Care and Health Research Clinical Research Centre (NISCHR CRC).  
 
The central imaging work was undertaken at the Brain Imaging Research Centre 
(www.bric.ed.ac.uk), a member of the Scottish Imaging Network A Platform for Scientific 
Excellence (SINAPSE) collaboration (www.sinapse.ac.uk), at the Division of Clinical 
Neurosciences, University of Edinburgh. SINAPSE is funded by the Scottish Funding Council 
(SFC) and the Chief Scientist Office of the Scottish Executive (CSO).  
 
Additional support was received from Chest Heart and Stroke Scotland, DesAcc, University of 
Edinburgh, Danderyd Hospital Research & Development Department, Karolinska Institutet, 
Oslo University Hospital, and the Dalhousie University Internal Medicine Research Fund.  
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